These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 27112322)

  • 1. MIDAS: a practical Bayesian design for platform trials with molecularly targeted agents.
    Yuan Y; Guo B; Munsell M; Lu K; Jazaeri A
    Stat Med; 2016 Sep; 35(22):3892-906. PubMed ID: 27112322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Bayesian adaptive phase I/II platform trial design for pediatric immunotherapy trials.
    Mu R; Pan H; Xu G
    Stat Med; 2021 Jan; 40(2):382-402. PubMed ID: 33094528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A robust two-stage design identifying the optimal biological dose for phase I/II clinical trials.
    Zang Y; Lee JJ
    Stat Med; 2017 Jan; 36(1):27-42. PubMed ID: 27538818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ComPAS: A Bayesian drug combination platform trial design with adaptive shrinkage.
    Tang R; Shen J; Yuan Y
    Stat Med; 2019 Mar; 38(7):1120-1134. PubMed ID: 30419609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SPIRIT: A seamless phase I/II randomized design for immunotherapy trials.
    Guo B; Li D; Yuan Y
    Pharm Stat; 2018 Sep; 17(5):527-540. PubMed ID: 29882388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Shotgun: A Bayesian seamless phase I-II design to accelerate the development of targeted therapies and immunotherapy.
    Jiang L; Li R; Yan F; Yap TA; Yuan Y
    Contemp Clin Trials; 2021 May; 104():106338. PubMed ID: 33711459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlled multi-arm platform design using predictive probability.
    Hobbs BP; Chen N; Lee JJ
    Stat Methods Med Res; 2018 Jan; 27(1):65-78. PubMed ID: 26763586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Bayesian adaptive phase I-II trial design for optimizing the schedule of therapeutic cancer vaccines.
    Cunanan KM; Koopmeiners JS
    Stat Med; 2017 Jan; 36(1):43-53. PubMed ID: 27545299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of a multi-arm multi-stage Bayesian design for phase II drug selection trials - an example in hemato-oncology.
    Jacob L; Uvarova M; Boulet S; Begaj I; Chevret S
    BMC Med Res Methodol; 2016 Jun; 16():67. PubMed ID: 27250349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BASIC: A Bayesian adaptive synthetic-control design for phase II clinical trials.
    Jiang L; Thall PF; Yan F; Kopetz S; Yuan Y
    Clin Trials; 2023 Oct; 20(5):486-496. PubMed ID: 37313712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficiencies of platform clinical trials: A vision of the future.
    Saville BR; Berry SM
    Clin Trials; 2016 Jun; 13(3):358-66. PubMed ID: 26908536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single arm two-stage studies: Improved designs for molecularly targeted agents.
    Dutton P; Holmes J
    Pharm Stat; 2018 Nov; 17(6):761-769. PubMed ID: 30112838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of multi-arm multi-stage design and adaptive randomization in platform clinical trials.
    Lin J; Bunn V
    Contemp Clin Trials; 2017 Mar; 54():48-59. PubMed ID: 28089763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MIDAS-2: an enhanced Bayesian platform design for immunotherapy combinations with subgroup efficacy exploration.
    Su L; Chen X; Zhang J; Yan F
    J Biopharm Stat; 2023 Dec; ():1-21. PubMed ID: 38131109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A practical Bayesian design to identify the maximum tolerated dose contour for drug combination trials.
    Zhang L; Yuan Y
    Stat Med; 2016 Nov; 35(27):4924-4936. PubMed ID: 27580928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accounting for uncertainty in the historical response rate of the standard treatment in single-arm two-stage designs based on Bayesian power functions.
    Matano F; Sambucini V
    Pharm Stat; 2016 Nov; 15(6):517-530. PubMed ID: 27766770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials.
    Lin R; Yin G
    Stat Med; 2017 Nov; 36(26):4106-4120. PubMed ID: 28786138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of Bayesian hierarchical models for phase I/II clinical trials in oncology.
    Yada S; Hamada C
    Pharm Stat; 2017 Mar; 16(2):114-121. PubMed ID: 27892650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of an adaptive design to a randomized phase II selection trial in gastric cancer: a report of the study design.
    Morita S; Sakamoto J
    Pharm Stat; 2006; 5(2):109-18. PubMed ID: 17080767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bayesian adaptive phase II screening design for combination trials.
    Cai C; Yuan Y; Johnson VE
    Clin Trials; 2013; 10(3):353-62. PubMed ID: 23359875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.